SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on November 22, 2013. The registrant is headquartered in Sydney, Australia, and files annual reports on Form 20-F. The filing serves to disclose a specific corporate governance event rather than periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding director interests and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the submission of an "Appendix 3Z Final Director's Interest Notice" (Exhibit 99.1). This notice details changes or confirmations regarding the shareholdings or interests of the company's directors as required by Australian regulations.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the director's interest notice.
Key Facts for Investor Verification
- Verify the specific details of the Director's Interest Notice contained in Exhibit 99.1 to understand changes in director shareholdings.
- Confirm the identity of the signatory, Matthew Lehman, who signed the report as Chief Executive Officer.
- Note that this filing does not update the company's financial position or operational outlook.